Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Gut microbiome profiling and colorectal cancer in African Americans and Caucasian Americans.

Farhana L, Antaki F, Murshed F, Mahmud H, Judd SL, Nangia-Makker P, Levi E, Yu Y, Majumdar AP.

World J Gastrointest Pathophysiol. 2018 Sep 29;9(2):47-58. doi: 10.4291/wjgp.v9.i2.47.

2.

Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy.

Saadat N, Liu F, Haynes B, Nangia-Makker P, Bao X, Li J, Polin LA, Gupta S, Mao G, Shekhar MP.

Mol Cancer Ther. 2018 Dec;17(12):2586-2597. doi: 10.1158/1535-7163.MCT-18-0364. Epub 2018 Sep 21.

PMID:
30242094
3.

Galectin-3 and cancer stemness.

Nangia-Makker P, Hogan V, Raz A.

Glycobiology. 2018 Apr 1;28(4):172-181. doi: 10.1093/glycob/cwy001. Review.

4.

A novel mechanism of lncRNA and miRNA interaction: CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells.

Yu Y, Nangia-Makker P, Farhana L, Majumdar APN.

Mol Cancer. 2017 Sep 30;16(1):155. doi: 10.1186/s12943-017-0725-5.

5.

Cancer Self-Defense: An Immune Stealth.

Nakajima K, Nangia-Makker P, Hogan V, Raz A.

Cancer Res. 2017 Oct 15;77(20):5441-5444. doi: 10.1158/0008-5472.CAN-17-1324. Epub 2017 Aug 24. Review. Erratum in: Cancer Res. 2018 Jul 1;78(13):3743.

6.

Breast cancer complexity: implications of intratumoral heterogeneity in clinical management.

Haynes B, Sarma A, Nangia-Makker P, Shekhar MP.

Cancer Metastasis Rev. 2017 Sep;36(3):547-555. doi: 10.1007/s10555-017-9684-y. Review.

7.

Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.

Sanders MA, Haynes B, Nangia-Makker P, Polin LA, Shekhar MP.

J Biol Chem. 2017 Jun 23;292(25):10347-10363. doi: 10.1074/jbc.M117.792192. Epub 2017 May 10.

8.

Bile acid: a potential inducer of colon cancer stem cells.

Farhana L, Nangia-Makker P, Arbit E, Shango K, Sarkar S, Mahmud H, Hadden T, Yu Y, Majumdar AP.

Stem Cell Res Ther. 2016 Dec 1;7(1):181.

9.

Racial disparity in colorectal cancer: Gut microbiome and cancer stem cells.

Goyal S, Nangia-Makker P, Farhana L, Yu Y, Majumdar AP.

World J Stem Cells. 2016 Sep 26;8(9):279-87. doi: 10.4252/wjsc.v8.i9.279. Review.

10.

Role of cancer stem cells in racial disparity in colorectal cancer.

Farhana L, Antaki F, Anees MR, Nangia-Makker P, Judd S, Hadden T, Levi E, Murshed F, Yu Y, Van Buren E, Ahmed K, Dyson G, Majumdar AP.

Cancer Med. 2016 Jun;5(6):1268-78. doi: 10.1002/cam4.690. Epub 2016 Mar 14.

11.

Role of cancer stem cells in age-related rise in colorectal cancer.

Nangia-Makker P, Yu Y, Majumdar AP.

World J Gastrointest Pathophysiol. 2015 Nov 15;6(4):86-9. doi: 10.4291/wjgp.v6.i4.86.

12.

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.

Goodson WH 3rd, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami GN, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP Sr, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart ME, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson PA, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom SE, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z.

Carcinogenesis. 2015 Jun;36 Suppl 1:S254-96. doi: 10.1093/carcin/bgv039. Review. Erratum in: Carcinogenesis. 2016 Mar;37(3):344.

13.

The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis.

Ochieng J, Nangami GN, Ogunkua O, Miousse IR, Koturbash I, Odero-Marah V, McCawley LJ, Nangia-Makker P, Ahmed N, Luqmani Y, Chen Z, Papagerakis S, Wolf GT, Dong C, Zhou BP, Brown DG, Colacci AM, Hamid RA, Mondello C, Raju J, Ryan EP, Woodrick J, Scovassi AI, Singh N, Vaccari M, Roy R, Forte S, Memeo L, Salem HK, Amedei A, Al-Temaimi R, Al-Mulla F, Bisson WH, Eltom SE.

Carcinogenesis. 2015 Jun;36 Suppl 1:S128-59. doi: 10.1093/carcin/bgv034. Review.

14.

miR-21 and miR-145 cooperation in regulation of colon cancer stem cells.

Yu Y, Nangia-Makker P, Farhana L, G Rajendra S, Levi E, Majumdar AP.

Mol Cancer. 2015 May 1;14:98. doi: 10.1186/s12943-015-0372-7.

15.

Glycodendrimers and Modified ELISAs: Tools to Elucidate Multivalent Interactions of Galectins 1 and 3.

Wolfenden M, Cousin J, Nangia-Makker P, Raz A, Cloninger M.

Molecules. 2015 Apr 20;20(4):7059-96. doi: 10.3390/molecules20047059.

16.

Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer.

Vasudevan A, Yu Y, Banerjee S, Woods J, Farhana L, Rajendra SG, Patel A, Dyson G, Levi E, Maddipati KR, Majumdar AP, Nangia-Makker P.

Cancer Prev Res (Phila). 2014 Nov;7(11):1138-48. doi: 10.1158/1940-6207.CAPR-14-0177. Epub 2014 Sep 5.

17.

Multivalent scaffolds induce galectin-3 aggregation into nanoparticles.

Goodman CK, Wolfenden ML, Nangia-Makker P, Michel AK, Raz A, Cloninger MJ.

Beilstein J Org Chem. 2014 Jul 10;10:1570-7. doi: 10.3762/bjoc.10.162. eCollection 2014.

18.

Lactose-functionalized dendrimers arbitrate the interaction of galectin-3/MUC1 mediated cancer cellular aggregation.

Michel AK, Nangia-Makker P, Raz A, Cloninger MJ.

Chembiochem. 2014 Sep 22;15(14):2106-12. doi: 10.1002/cbic.201402134. Epub 2014 Aug 19.

19.

Galectin-3 in angiogenesis and metastasis.

Funasaka T, Raz A, Nangia-Makker P.

Glycobiology. 2014 Oct;24(10):886-91. doi: 10.1093/glycob/cwu086. Epub 2014 Aug 18. Review.

20.

Nuclear transport of galectin-3 and its therapeutic implications.

Funasaka T, Raz A, Nangia-Makker P.

Semin Cancer Biol. 2014 Aug;27:30-8. doi: 10.1016/j.semcancer.2014.03.004. Epub 2014 Mar 19. Review.

21.

Metformin: a potential therapeutic agent for recurrent colon cancer.

Nangia-Makker P, Yu Y, Vasudevan A, Farhana L, Rajendra SG, Levi E, Majumdar AP.

PLoS One. 2014 Jan 20;9(1):e84369. doi: 10.1371/journal.pone.0084369. eCollection 2014.

22.

Galectin-3: a possible complementary marker to the PSA blood test.

Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, Heilbrun L, Raz A, Heath E.

Oncotarget. 2013 Apr;4(4):542-9.

23.
24.

Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases.

Nangia-Makker P, Raz T, Tait L, Shekhar MP, Li H, Balan V, Makker H, Fridman R, Maddipati K, Raz A.

Cancer Biol Ther. 2013 May;14(5):417-27. doi: 10.4161/cbt.23762. Epub 2013 Feb 4.

25.

Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization.

Sanders MA, Brahemi G, Nangia-Makker P, Balan V, Morelli M, Kothayer H, Westwell AD, Shekhar MPV.

Mol Cancer Ther. 2013 Apr;12(4):373-83. doi: 10.1158/1535-7163.MCT-12-0793. Epub 2013 Jan 21.

26.

Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells.

Kho DH, Nangia-Makker P, Balan V, Hogan V, Tait L, Wang Y, Raz A.

Cancer Res. 2013 Feb 15;73(4):1411-9. doi: 10.1158/0008-5472.CAN-12-2149. Epub 2012 Dec 17.

27.

Galectin-3 regulates p21 stability in human prostate cancer cells.

Wang Y, Balan V, Kho D, Hogan V, Nangia-Makker P, Raz A.

Oncogene. 2013 Oct 17;32(42):5058-65. doi: 10.1038/onc.2012.528. Epub 2012 Nov 19.

28.

Galectin-3 binding and metastasis.

Nangia-Makker P, Balan V, Raz A.

Methods Mol Biol. 2012;878:251-66. doi: 10.1007/978-1-61779-854-2_17.

29.

Tyrosine-phosphorylated galectin-3 protein is resistant to prostate-specific antigen (PSA) cleavage.

Balan V, Nangia-Makker P, Kho DH, Wang Y, Raz A.

J Biol Chem. 2012 Feb 17;287(8):5192-8. doi: 10.1074/jbc.C111.331686. Epub 2012 Jan 9.

30.

Rad6B acts downstream of Wnt signaling to stabilize β-catenin: Implications for a novel Wnt/β-catenin target.

Gerard B, Tait L, Nangia-Makker P, Shekhar MP.

J Mol Signal. 2011 Jul 18;6:6. doi: 10.1186/1750-2187-6-6.

31.

Galectin-3: A novel substrate for c-Abl kinase.

Balan V, Nangia-Makker P, Jung YS, Wang Y, Raz A.

Biochim Biophys Acta. 2010 Oct;1803(10):1198-205. doi: 10.1016/j.bbamcr.2010.06.007. Epub 2010 Jun 30.

32.

Galectins as cancer biomarkers.

Balan V, Nangia-Makker P, Raz A.

Cancers (Basel). 2010 Apr 20;2(2):592-610. doi: 10.3390/cancers2020592.

33.

Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer.

Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V, Raz A.

Int J Cancer. 2010 Dec 1;127(11):2530-41. doi: 10.1002/ijc.25254.

34.

Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment.

Wang Y, Nangia-Makker P, Balan V, Hogan V, Raz A.

Cell Death Dis. 2010 Nov 18;1:e101. doi: 10.1038/cddis.2010.79.

35.

Regulation of tumor progression by extracellular galectin-3.

Nangia-Makker P, Balan V, Raz A.

Cancer Microenviron. 2008 Dec;1(1):43-51. doi: 10.1007/s12307-008-0003-6. Epub 2008 Feb 20.

36.

Regulation of prostate cancer progression by galectin-3.

Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, Pienta KJ, Raz A.

Am J Pathol. 2009 Apr;174(4):1515-23. doi: 10.2353/ajpath.2009.080816. Epub 2009 Mar 12.

37.

Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study.

Balan V, Nangia-Makker P, Schwartz AG, Jung YS, Tait L, Hogan V, Raz T, Wang Y, Yang ZQ, Wu GS, Guo Y, Li H, Abrams J, Couch FJ, Lingle WL, Lloyd RV, Ethier SP, Tainsky MA, Raz A.

Cancer Res. 2008 Dec 15;68(24):10045-50. doi: 10.1158/0008-5472.CAN-08-3224.

38.

Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death.

Shekhar MP, Tait L, Pauley RJ, Wu GS, Santner SJ, Nangia-Makker P, Shekhar V, Nassar H, Visscher DW, Heppner GH, Miller FR.

Cancer Biol Ther. 2008 Nov;7(11):1774-82. Epub 2008 Nov 12.

39.

Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers.

Nangia-Makker P, Raz T, Tait L, Hogan V, Fridman R, Raz A.

Cancer Res. 2007 Dec 15;67(24):11760-8.

40.

Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum.

Nangia-Makker P, Tait L, Shekhar MP, Palomino E, Hogan V, Piechocki MP, Funasaka T, Raz A.

Int J Cancer. 2007 Aug 15;121(4):884-94.

41.

Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells.

Mazurek N, Sun YJ, Liu KF, Gilcrease MZ, Schober W, Nangia-Makker P, Raz A, Bresalier RS.

J Biol Chem. 2007 Jul 20;282(29):21337-48. Epub 2007 Apr 9.

42.

Galectin-3 in apoptosis, a novel therapeutic target.

Nangia-Makker P, Nakahara S, Hogan V, Raz A.

J Bioenerg Biomembr. 2007 Feb;39(1):79-84. Review.

43.

Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer.

Fukumori T, Oka N, Takenaka Y, Nangia-Makker P, Elsamman E, Kasai T, Shono M, Kanayama HO, Ellerhorst J, Lotan R, Raz A.

Cancer Res. 2006 Mar 15;66(6):3114-9.

44.

Phosphorylation of galectin-3 contributes to malignant transformation of human epithelial cells via modulation of unique sets of genes.

Mazurek N, Sun YJ, Price JE, Ramdas L, Schober W, Nangia-Makker P, Byrd JC, Raz A, Bresalier RS.

Cancer Res. 2005 Dec 1;65(23):10767-75.

46.

Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin.

Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A.

J Natl Cancer Inst. 2002 Dec 18;94(24):1854-62.

PMID:
12488479
47.

Carbohydrate-binding proteins in cancer, and their ligands as therapeutic agents.

Nangia-Makker P, Conklin J, Hogan V, Raz A.

Trends Mol Med. 2002 Apr;8(4):187-92.

PMID:
11927277
48.

Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells.

Honjo Y, Nangia-Makker P, Inohara H, Raz A.

Clin Cancer Res. 2001 Mar;7(3):661-8.

49.

Carbohydrate-recognition and angiogenesis.

Nangia-Makker P, Baccarini S, Raz A.

Cancer Metastasis Rev. 2000;19(1-2):51-7. Review.

PMID:
11191063
50.

Galectin-3 binding and metastasis.

Nangia-Makker P, Honjo Y, Raz A.

Methods Mol Med. 2001;58:149-57. doi: 10.1385/1-59259-137-X:149.

PMID:
21340855

Supplemental Content

Loading ...
Support Center